$VCYT News
Last published 1d ago
- 1d agoVCYTUBS Global Healthcare Conference - VERACYTE INCEarnings Call TranscriptsAll right. Good afternoon. My name is Doug Schenkel. It's my pleasure to welcome, on behalf of UBS, Mark Stapley, Chief Executive Officer, and Rebecca Chambers, Chief Financial Officer from VeriSight. Thanks to both of y
- 1d agoVCYTUBS Global Healthcare Conference - VERACYTE INCEarnings Call TranscriptsAll right. Good afternoon. My name is Doug Schenkel. It's my pleasure to welcome, on behalf of UBS, Mark Stapley, Chief Executive Officer, and Rebecca Chambers, Chief Financial Officer from VeriSight. Thanks to both of y
- 1w agoVCYTVERACYTE, INC. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 8.01 Item 9.01
- 1w agoVCYTVeracyte Announces Third Quarter 2026 Financial ResultsGlobeNewswireGrew total revenue to $151.8 million and testing revenue to $146.4 million, representing 15% year-over-year growth Announces $100 million share repurchase program SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE
- 1w agoVCYTTen Afirma Abstracts to Highlight Thyroid Nodule Diagnosis and Cancer Research at ATA 2026GlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced that 10 abstracts involving its Afirma thyroid test will be presented
- 1w agoVCYTVeracyte to Participate in Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced it will be participating in the following investor conferences: UBS
- 2w agoVCYTPhase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate CancerGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced new data showing that its Decipher® Prostate Genomic Classifier can
- 3w agoVCYTSix Studies to Highlight Veracyte’s Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026GlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced that six studies involving its genomic tests will be presented at the
- 3w agoVCYTVeracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence TestGlobeNewswireSOUTH SAN FRANCISCO, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced that its Prosigna® Breast Risk of Recurrence (ROR) test has received coverage
- 4w agoVCYTVeracyte to Release Third Quarter 2026 Financial Results on November 4, 2026GlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter 2026
- 1mo agoVCYTVeracyte, Inc. - 1773732 - VERACYTE INCEarnings Call TranscriptsOkay, I think we'll kick things off here. My name is Jacob Dodd. I work with Callum Titchmarsh here on the Life Science Tools and Diagnostics team at Morgan Stanley. Thank you all for joining us here this morning. We're
- 1mo agoVCYTMorgan Stanley 24th Annual Global Healthcare Conference - VERACYTE INCEarnings Call TranscriptsOkay, I think we'll kick things off here. My name is Jacob Dodd. I work with Callum Titchmarsh here on the Life Science Tools and Diagnostics team at Morgan Stanley. Thank you all for joining us here this morning. We're
- 1mo agoVCYTMorgan Stanley 24th Annual Global Healthcare Conference - VERACYTE INCEarnings Call TranscriptsOkay, I think we'll kick things off here. My name is Jacob Dodd. I work with Callum Titchmarsh here on the Life Science Tools and Diagnostics team at Morgan Stanley. Thank you all for joining us here this morning. We're
- 1mo agoVCYTVeracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing PlatformGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced its acquisition of Convergent Genomics. The acquisition adds
- 2mo agoVCYTVeracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced it will participate in a fireside chat at the Morgan Stanley 24th
- 3mo agoVCYTCG 46TH ANNUAL GROWTH CONFERENCE - VERACYTE INCEarnings Call TranscriptsHi, welcome to the Canaccord GED Growth Conference. I'm Kyle Mixon. I cover life science tools and diagnosis for Canaccord. Please welcome you to a Farrisite chat with Verisite. Here with us today, VerisITE offers a broa
- 3mo agoVCYTCG 46TH ANNUAL GROWTH CONFERENCE - VERACYTE INCEarnings Call TranscriptsHi, welcome to the Canaccord GED Growth Conference. I'm Kyle Mixon. I cover life science tools and diagnosis for Canaccord. Please welcome you to a Farrisite chat with Verisite. Here with us today, VerisITE offers a broa
- 3mo agoVCYTVeracyte Announces Second Quarter 2026 Financial ResultsGlobeNewswireGrew total revenue to $150.3 million and testing revenue to $145.7 million, representing increases of 15% and 19% year-over-year, respectivelyConference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO,
- 3mo agoVCYTVeracyte to Participate in Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that it will be participating in the following investor conferences:
- 4mo agoVCYTVeracyte to Release Second Quarter 2026 Financial Results on July 30, 2026Business WireVeracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the second quarter 2026 after the close of market on Thursday, July 30, 2026. Company
- 5mo agoVCYTVeracyte Investor Call on ASCO FindingsVERACYTE INCEarnings Call TranscriptsGood day and thank you for standing by. Welcome to the VeriSight Investor Call on ASCO Findings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a
- 5mo agoVCYTVeracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.Business WireGenomic test using whole-transcriptome next-generation sequencing technology will be available to order on June 8 The Prosigna test predicts chemotherapy benefit and quantifies 10-year risk of recurrence to help
- 5mo agoVCYTENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate CancerBusiness WireStudy provides first Level 1B evidence for genomic-guided decisions on triplet therapy in advanced disease Additional ASCO data reinforce Decipher Prostate's utility in high-risk localized disease Veracyte, Inc.
- 5mo agoVCYTLandmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte's Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid ChemotherapyBusiness WireHighest level of prospective evidence supports test-directed chemotherapy decisions in broadest high-risk population to-date, including premenopausal women and patients with extensive lymph node involvement Study
- 5mo agoVCYTVeracyte to Host Investor Call on June 1, 2026 to Discuss ASCO FindingsBusiness WireVeracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced that it will host a conference call and webcast on Monday, June 1, 2026 at 8:30 a.m. ET to discuss data from two significant phase III
- 5mo agoVCYTOPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast CancerBusiness WireAdditional Data from ENZAMET Study Show How Decipher Can Help Metastatic Prostate Cancer Patients Avoid Unnecessary Treatment and Enable More Personalized Care Veracyte, Inc. (NASDAQ:VCYT), a leading cancer
- 5mo agoVCYTVeracyte to Participate in Upcoming Investor ConferencesBusiness WireVeracyte, Inc. (NASDAQ:VCYT) announced today that the company will be participating in the following investor conferences. William Blair 46th Annual Growth Stock Conference – Chicago, IL Presentation on Tuesday, June
- 6mo agoVCYTVeracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder CancerBusiness WireMarks the first Medicare coverage decision for Veracyte's whole-genome sequencing-based TrueMRD platform and launch of the first test Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced
- 6mo agoBFLYCTKBHTFLVCYT+1A Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in MedtechGlobeNewswireVMS+™ 4.0 system collects a 2026 Edison Award Gold Medal, advances to NMPA regulatory submission in China, and heads to the AEPC pediatric cardiology meeting in Padua, Italy VANCOUVER, British Columbia, May
- 6mo agoVCYTVeracyte First Quarter 2026 Financial Results WebcastVERACYTE INCEarnings Call TranscriptsGood day and thank you for standing by. Welcome to VeriSight First Quarter 2026 Financial Results Webcast Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a
- 6mo agoVCYTVeracyte Announces First Quarter 2026 Financial ResultsBusiness WireGrew total revenue to $139.1 million and testing revenue to $135.1 million, representing increases of 21% and 26% year-over-year, respectively Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc.
- 6mo agoVCYTVeracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic CancersBusiness WireStudies demonstrate clinical utility of Decipher Bladder molecular subtyping in bladder cancer and the expanding impact of Decipher Prostate in studies using real-world data Veracyte, Inc. (NASDAQ:VCYT), a leading
- 7mo agoVCYTVeracyte to Release First Quarter 2026 Financial Results on May 5, 2026Business WireVeracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the first quarter 2026 after the close of market on Tuesday, May 5, 2026. Company management
- 8mo agoVCYTVeracyte Names Kevin Haas as Chief Development and Technology OfficerBusiness WireVeracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that Kevin Haas, Ph.D., has been appointed Chief Development and Technology Officer, a newly created leadership role designed to
- 8mo agoVCYTVeracyte Fourth Quarter 2025 Financial Results WebcastVERACYTE INCEarnings Call TranscriptsGood day and thank you for standing by. Welcome to the Verisight 4th Quarter 2025 Financial Results Webcast. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a que
- 8mo agoVCYTVeracyte Announces Fourth Quarter and Full Year 2025 Financial ResultsBusiness WireGrew fourth quarter total revenue to $140.6 million, an increase of 19% Grew fourth quarter testing revenue to $135.8 million, an increase of 21% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc.
- 8mo agoVCYTVeracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU SymposiumBusiness WireMore than 15 abstracts showcase how the Veracyte Diagnostics Platform is advancing urologic cancer care with decisions guided by Decipher Prostate and Bladder tests Veracyte, Inc. (NASDAQ:VCYT), a leading cancer
- 8mo agoVCYTVeracyte to Participate in Upcoming Investor ConferencesBusiness WireVeracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today it will participate in the following investor conferences. Raymond James 47th Annual Institutional Investors Conference – Orlando,
- 10mo agoVCYTVeracyte Announces Preliminary Fourth Quarter and Full-Year 2025 ResultsBusiness WireGrew full-year revenue to between $515 million and $517 million, an increase of 16% Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced preliminary, unaudited financial results for the
- 10mo agoONCYEXASVCYTHOLX+1Smart Oncology: 5 Stocks Chasing the $317B PrizePR NewswireThe precision oncology market surged to $139.4 billion in 2025 and is racing toward $317.5 billion by 2035[1], driven by a fundamental shift in...
- 10mo agoVCYTVeracyte to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceBusiness WireVeracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 9:45 a.m. Pacific
- 1y agoVCYTVeracyte to Participate in Upcoming Investor ConferencesBusiness WireVeracyte, Inc. (NASDAQ:VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. Wolfe Research Healthcare Conference – New York, NY Fireside Chat on
- 1y agoVCYTVeracyte Announces Third Quarter 2025 Financial ResultsBusiness WireGrew total revenue to $131.9 million and testing revenue to $127.8 million, representing increases of 14% and 17% year-over-year, respectively Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc.
- 1y agoVCYTVeracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule TestingBusiness WireLandmark studies leverage Afirma GRID whole transcriptome-derived data to identify molecular classifiers and signatures differentiating thyroid cancer risk groups Veracyte, Inc. (NASDAQ:VCYT), a leading genomic
- 1y agoVCYTVeracyte to Release Third Quarter 2025 Financial Results on November 4, 2025Business WireVeracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter of 2025 after the close of market on Tuesday, November 4, 2025. Company
- 1y agoVCYTVeracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate CancerBusiness WireFindings from the first prospective validation trial for biomarker presented at ASTRO 2025
- 1y agoQUREVCYTHUMEDITHealthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention FocusPR NewswireAmerica's aging demographics are creating unprecedented demand for precision healthcare solutions, with population projections showing nearly one in...
- 1y agoVCYTVeracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025Business WireFindings are among nine Decipher-focused abstracts being presented at annual conference Veracyte, Inc. (NASDAQ:VCYT), a leading genomic diagnostics company, announced today that the first prospective validation data
- 1y agoVCYTVeracyte, Inc. (VCYT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoVCYTVeracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual MeetingBusiness WireStudies leverage company's Afirma Genomic Resource for Intelligent Discovery (GRID), world's largest molecular database for thyroid nodules Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today